Search
Showing results for "1"
News & Events
Diabetes Research WA Grant for Dr Mary AbrahamPerth researchers have been awarded new West Australian funding to launch a pilot study into the use of oral insulin in type 1 diabetes – a medication intervention that could be a game-changer for those with the chronic condition.
News & Events
Centre's research in the spotlightThe Children’s Diabetes Centre showcased its progress in paediatric Type 1 Diabetes research at a JDRF Australia event held at The Kids Research Institute Australia recently.
Research
The anti-inflammatory effects of interleukin-4 are not mediated by suppressor of cytokine signalling-1 (SOCS1)While it is known that the anti-inflammatory effects of interleukin (IL)-4 require new protein synthesis, the exact mechanisms by which IL-4 suppresses the prod
Research
The importance of environment on respiratory genotype/phenotype relationships in the InuitThis study aimed to investigate the effects of different macro-environments on asthma genotype-phenotype associations in 2 geographically separated populations
Research
ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetesHypoglycemia is the commonest acute complication of type 1 diabetes
News & Events
Congratulations Centre ResearchersCentre researchers awarded external travel grants to attend international conferences
News & Events
Exercise summit wrap upThe Children’s Diabetes Centre recently held summits for young people with Type 1 Diabetes to get their input into the development of new exercise guidelines.
The WAACHS regional profiles look at all four volumes of results across the ATSIC regions of Western Australia.
Research
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.
